These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 30918126)

  • 1. BRCA1/BARD1-dependent ubiquitination of NF2 regulates Hippo-YAP1 signaling.
    Verma S; Yeddula N; Soda Y; Zhu Q; Pao G; Moresco J; Diedrich JK; Hong A; Plouffe S; Moroishi T; Guan KL; Verma IM
    Proc Natl Acad Sci U S A; 2019 Apr; 116(15):7363-7370. PubMed ID: 30918126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Merlin/NF2 loss-driven tumorigenesis linked to CRL4(DCAF1)-mediated inhibition of the hippo pathway kinases Lats1 and 2 in the nucleus.
    Li W; Cooper J; Zhou L; Yang C; Erdjument-Bromage H; Zagzag D; Snuderl M; Ladanyi M; Hanemann CO; Zhou P; Karajannis MA; Giancotti FG
    Cancer Cell; 2014 Jul; 26(1):48-60. PubMed ID: 25026211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. β1 integrin-dependent Rac/group I PAK signaling mediates YAP activation of Yes-associated protein 1 (YAP1) via NF2/merlin.
    Sabra H; Brunner M; Mandati V; Wehrle-Haller B; Lallemand D; Ribba AS; Chevalier G; Guardiola P; Block MR; Bouvard D
    J Biol Chem; 2017 Nov; 292(47):19179-19197. PubMed ID: 28972170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum deprivation inhibits the transcriptional co-activator YAP and cell growth via phosphorylation of the 130-kDa isoform of Angiomotin by the LATS1/2 protein kinases.
    Adler JJ; Johnson DE; Heller BL; Bringman LR; Ranahan WP; Conwell MD; Sun Y; Hudmon A; Wells CD
    Proc Natl Acad Sci U S A; 2013 Oct; 110(43):17368-73. PubMed ID: 24101513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hippo pathway inactivation through subcellular localization of NF2/merlin in outer cells of mouse embryos.
    Goda N; Ito Y; Saito S; Suzuki M; Bai H; Takahashi M; Wakai T; Kawahara M
    Development; 2024 Jul; 151(14):. PubMed ID: 39077779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Hippo pathway member Nf2 is required for inner cell mass specification.
    Cockburn K; Biechele S; Garner J; Rossant J
    Curr Biol; 2013 Jul; 23(13):1195-201. PubMed ID: 23791728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The ubiquitin E3 ligase ITCH enhances breast tumor progression by inhibiting the Hippo tumor suppressor pathway.
    Salah Z; Itzhaki E; Aqeilan RI
    Oncotarget; 2014 Nov; 5(21):10886-900. PubMed ID: 25350971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Statin suppresses Hippo pathway-inactivated malignant mesothelioma cells and blocks the YAP/CD44 growth stimulatory axis.
    Tanaka K; Osada H; Murakami-Tonami Y; Horio Y; Hida T; Sekido Y
    Cancer Lett; 2017 Jan; 385():215-224. PubMed ID: 27773750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blockade of a novel MAP4K4-LATS2-SASH1-YAP1 cascade inhibits tumorigenesis and metastasis in luminal breast cancer.
    Yang P; Li Y; Hou J; Wu D; Zeng X; Zeng Z; Zhang J; Xiong Y; Chen L; Yang D; Wan X; Wu Z; Jia L; Liu Q; Lu Q; Zou X; Fang W; Zeng X; Zhou D
    J Biol Chem; 2024 Jun; 300(6):107309. PubMed ID: 38657867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Negative feedback loop of BRCA1-BARD1 ubiquitin ligase on estrogen receptor alpha stability and activity antagonized by cancer-associated isoform of BARD1.
    Dizin E; Irminger-Finger I
    Int J Biochem Cell Biol; 2010 May; 42(5):693-700. PubMed ID: 20060929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TGF-β Targets the Hippo Pathway Scaffold RASSF1A to Facilitate YAP/SMAD2 Nuclear Translocation.
    Pefani DE; Pankova D; Abraham AG; Grawenda AM; Vlahov N; Scrace S; O' Neill E
    Mol Cell; 2016 Jul; 63(1):156-66. PubMed ID: 27292796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypoxia regulates Hippo signalling through the SIAH2 ubiquitin E3 ligase.
    Ma B; Chen Y; Chen L; Cheng H; Mu C; Li J; Gao R; Zhou C; Cao L; Liu J; Zhu Y; Chen Q; Wu S
    Nat Cell Biol; 2015 Jan; 17(1):95-103. PubMed ID: 25438054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Merlin/NF2-Lin28B-let-7 Is a Tumor-Suppressive Pathway that Is Cell-Density Dependent and Hippo Independent.
    Hikasa H; Sekido Y; Suzuki A
    Cell Rep; 2016 Mar; 14(12):2950-61. PubMed ID: 26997273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The BRCA1/BARD1 ubiquitin ligase and its substrates.
    Witus SR; Stewart MD; Klevit RE
    Biochem J; 2021 Sep; 478(18):3467-3483. PubMed ID: 34591954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hippo pathway gene mutations in malignant mesothelioma: revealed by RNA and targeted exon sequencing.
    Miyanaga A; Masuda M; Tsuta K; Kawasaki K; Nakamura Y; Sakuma T; Asamura H; Gemma A; Yamada T
    J Thorac Oncol; 2015 May; 10(5):844-851. PubMed ID: 25902174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BARD1 is necessary for ubiquitylation of nucleosomal histone H2A and for transcriptional regulation of estrogen metabolism genes.
    Stewart MD; Zelin E; Dhall A; Walsh T; Upadhyay E; Corn JE; Chatterjee C; King MC; Klevit RE
    Proc Natl Acad Sci U S A; 2018 Feb; 115(6):1316-1321. PubMed ID: 29367421
    [TBL] [Abstract][Full Text] [Related]  

  • 17. STUB1 suppresseses tumorigenesis and chemoresistance through antagonizing YAP1 signaling.
    Tang DE; Dai Y; Lin LW; Xu Y; Liu DZ; Hong XP; Jiang HW; Xu SH
    Cancer Sci; 2019 Oct; 110(10):3145-3156. PubMed ID: 31393050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. YAP1 recruits c-Abl to protect angiomotin-like 1 from Nedd4-mediated degradation.
    Skouloudaki K; Walz G
    PLoS One; 2012; 7(4):e35735. PubMed ID: 22558212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunohistochemistry for NF2, LATS1/2, and YAP/TAZ Fails to Separate Benign From Malignant Mesothelial Proliferations.
    Sheffield BS; Lorette J; Shen Y; Marra MA; Churg A
    Arch Pathol Lab Med; 2016 May; 140(5):391. PubMed ID: 27128293
    [No Abstract]   [Full Text] [Related]  

  • 20. FOXK2 transcription factor suppresses ERα-positive breast cancer cell growth through down-regulating the stability of ERα via mechanism involving BRCA1/BARD1.
    Liu Y; Ao X; Jia Z; Bai XY; Xu Z; Hu G; Jiang X; Chen M; Wu H
    Sci Rep; 2015 Mar; 5():8796. PubMed ID: 25740706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.